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Abstract 
Background: Attention deficit hyperactivity disorder (ADHD) is a prevalent and multifactorial neuropsychiatric disor-
der in the human population worldwide. Complex etiology and clinical heterogeneity have challenged the research, 
diagnostics and treatment of the disease. Hyperactive and impulsive behaviour has also been observed in dogs, and 
they could offer a physiologically relevant model for human ADHD. As a part of our ongoing study to understand the 
molecular etiology of canine anxiety traits, this study was aimed to pilot an approach to identify metabolic biomarkers 
in canine ADHD-like behaviours for research, diagnostics and treatment purposes.
Methods: We collected fresh plasma samples from 22 German Shepherds with varying ADHD-like behaviours. All 
dogs were on the same controlled diet for 2 weeks prior to sampling. A liquid chromatography combined with mass 
spectrometry (LC–MS)-based non-targeted metabolite profiling was performed to identify plasma metabolites cor-
relating with the ADHD-like behaviour of the dogs.
Results: 649 molecular features correlated with ADHD-like behavioural scores (praw < 0.05), and three of them [sn-1 
LysoPC(18:3), PC(18:3/18:2) and sn-1 LysoPE(18:2)] had significant correlations also after FDR correction (pFDR < 0.05). 
Phospholipids were found to negatively correlate with ADHD-like behavioural scores, whereas tryptophan metabo-
lites 3-indolepropionic acid (IPA) and kynurenic acid (KYNA) had negative and positive correlations with ADHD-like 
behavioural scores, respectively.
Conclusions: Our study identified associations between canine ADHD-like behaviours and metabolites that are 
involved in lipid and tryptophan metabolisms. The identified metabolites share similarity with earlier findings in 
human and rodent ADHD models. However, a larger replication study is warranted to validate the discoveries prior to 
further studies to understand the biological role of the identified metabolites in canine ADHD-like behaviours.
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Background
Attention deficit hyperactivity disorder (ADHD) is a 
multifactorial neuropsychiatric disorder with a high 
prevalence (5–10 %) among children worldwide. It is also 
increasingly reported in adults [1–3]. In general, ADHD is 
defined by age-inappropriate levels of inattention, impul-
sivity and hyperactivity [4]. The symptoms can be disa-
bling, interfering with normal everyday life [5]. Moreover, 
ADHD tends to comorbid with other neuropsychiatric 
disorders such as anxiety disorders [4]. Although we know 
that ADHD is highly heritable with mean heritability esti-
mates of 0.7, the exact molecular mechanisms underlying 
ADHD pathology are still not properly understood due to 
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the genetic complexity and interactions between genetic 
and environmental factors [3, 4, 6]. However, studies sug-
gest that disruptions in normal functions of dopaminer-
gic, serotonergic and noradrenergic systems may play a 
key role in ADHD pathogenesis [1, 3, 4].
One potential approach to unravel the biological path-
ways of ADHD is to utilise animal models, like dogs, 
which spontaneously show ADHD-like behaviours, such 
as hyperactivity, impulsivity and inattention. Many young 
dogs often show hyperactive and impulsive behaviour, 
but some hunting and working breeds, like the German 
Shepherd and the Belgian Shepherd, may continue to 
show these behavioural extremes later in life as well [7]. 
Due to the physiological similarities, dogs may serve as 
excellent natural large animal models of human ADHD. 
Moreover, genetic and pharmacological studies have 
already suggested that the underlying molecular mecha-
nisms of ADHD behaviours may be shared in dogs and 
humans [8]. Dogs with high impulsivity scores have been 
observed to have reduced tolerance for a delay in reward 
and also lower levels of urinary serotonin and serotonin/
dopamine ratio levels, thus, demonstrating convergent 
validity for canine model of impulsivity [9]. A dopamine 
transporter polymorphism was also found to associate 
with high activity levels in Belgian Malinois [10].
One of the challenges in ADHD research lies in the 
genetic complexity of the disorder. It is expected that 
multiple small effect genes contribute to ADHD sus-
ceptibility [3, 4]. There is a need either for large study 
cohorts or new natural models with a simpler genetic 
architecture such as dogs combined with complemen-
tary omics approaches. High-throughput technologies, 
such as metabolomics, may have the potential to facilitate 
ADHD research. Non-targeted metabolite profiling offers 
a hypothesis-free approach to detect altered metabolites 
and pathways in neuropsychiatric disorders. Few success-
ful examples exist and suggest genetic and environmental 
contributions to diseases [11–13].
In this study, we investigated the association between 
plasma metabolites and ADHD-like behavioural scores 
in diet-controlled dogs with varying ADHD-like behav-
iours in order to identify ADHD-related pathways and 
biomarker candidates using a LC-qTOF-MS –based 
approach. Our results reveal associations between 
ADHD-like behaviours and plasma phospholipids and 
tryptophan metabolites in dogs.
Methods
Animals and study design
Data on dog ADHD-like behaviour was collected using 
our validated owner-completed behavioural survey [14]. 
The questionnaire was advertised to Finnish dog own-
ers and breed clubs of all breeds via Facebook. Both dogs 
with hyperactive, impulsive and inattentive behaviours, 
as well as dogs with no sign of hyperactivity, impulsivity 
or inattention, were invited to participate in the survey.
The owner-completed behavioural survey included 
both general questions concerning the details of their 
dogs’ background, daily routines, and everyday behaviour 
and 13 more specific questions concerning the activity, 
impulsivity and inattention behaviour of the dog (Addi-
tional file  1: Table S1). In the questionnaire, we utilised 
the previously validated questions on impulsivity and 
activity levels in dogs [15, 16]. During data collection, 
the questionnaire was modified three times, resulting in 
four slightly different versions of the questionnaire (the 
first survey was a paper version, whereas the three oth-
ers were online questionnaires). The main questions 
regarding our target trait, ADHD-like behaviours, were 
not changed between the versions. The main difference 
came from adding further background questions to ver-
sions three and four (maternal care, place of birth, type 
of food, extra nutrients, time spent alone/day, daily exer-
cise) to better document the early life experiences and 
conditions of the dogs. To sort out the dogs with extreme 
ADHD-like behaviours, factor analysis was used to 
explore the factorial structure of the questionnaire, and 
to reveal possible interconnection between the questions 
concerning activity, impulsivity and inattention. The fac-
tor analysis (PROC FACTOR) was performed with SAS 
(version 9.3) and was conducted using the principal fac-
tor method with VARIMAX rotation. Based on the cri-
terion of eigenvalues  >1, all 13 questions were grouped 
into two factors, identified as ‘inattention’ and ‘impulsiv-
ity-activity’ (‘impulsivity-activity’ referred to as ‘impul-
sivity’ from now on). These two factors were very similar 
to factors found in the earlier studies [15, 16]. The ‘inat-
tention’—factor consisted of questions #1,2,3,4,7,10 and 
12, and the ‘impulsivity’—factor of questions #5,6,8,9 
and 13. Question #11 did not load with either factor and 
was excluded. Average scores for both inattention and 
impulsivity factors were calculated for each dog by sum-
ming up the points in each individual question and divid-
ing the result by the number of questions in the factor (7 
for ‘inattention’ and 5 for ‘impulsivity’). The total ADHD 
score consisting of the mean of the answers to all the 
13 questions concerning the hyperactive, impulsive and 
inattentive behaviour of the dog was defined for each dog 
to reflect the total ADHD-like status. All questions had 
four choices of increasing frequency (never =  1, some-
times = 2, often = 3, very often = 4). Higher scores rep-
resented higher ADHD-like behaviours.
Based on the ADHD-like behavioural scores, 22 pri-
vately-owned German Shepherds with scores varying 
from high to low, reflecting the ADHD-like behaviour 
of the dog, were recruited for the metabolomics study 
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(Additional file 2: Table S2). Furthermore, the behaviour 
of the selected dogs was confirmed by owner interviews. 
The age of the dogs varied from 16 to 91 months, where 
the mean age was 62 months (median 64.6 months). The 
data consisted of six males (mean age 58.3 months, rang-
ing from 16 to 86 months) and sixteen females (mean age 
63.4 months, ranging from 21 to 91 months). To control 
the possible effects of diet on the metabolite profiles, all 
recruited dogs were fed with the same commercial dry 
food (Royal Canin Maxi Sensible) for 2  weeks prior to 
sampling with 1 week as a run-in period, during which, 
the dogs adapted to the diet change. The owners were 
instructed not to use any other foods or dietary supple-
ments during the two-week period and were asked to 
report any changes. To investigate the metabolite pro-
files of the dogs, blood samples were collected from each 
dog by the same trained person followed by immediate 
isolation of plasma by a portable centrifuge. Plasma sam-
ples were kept on ice during shipping and stored in −20 
degrees (max 2 months) prior to metabolomics analysis. 
Most of the samples were taken at the dog’s home and 
two samples were taken in our laboratory. Samples were 
collected during the day and in the evening. Most of the 
dogs (19 out of 22) fasted 12  h before sampling. Sam-
ples were collected with the owners’ consent under valid 
ethical licenses (ESAVI/6054/04.10.03/2012 and Royal 
Canine ethical board 30052016).
Non‑targeted LC–MS metabolite profiling analysis
The sample preparation, instrument parameters and pre-
processing of raw data were performed in the LC–MS 
Metabolomics Center at Biocenter Kuopio (University 
of Eastern Finland), and they are previously presented in 
detail [17]. Briefly, methanol (300 µl) was used to precipi-
tate the proteins and extract the metabolites from plasma 
(100 µl). The non-targeted metabolite profiling was car-
ried out using the UHPLC-qTOF-MS system (Agilent 
Technologies, Waldbronn, Karlsruhe, Germany), which 
consisted of a 1290 LC system, a Jetstream electrospray 
ionization (ESI) source and a 6540 UHD accurate-mass 
quadrupole-time-of-flight (qTOF) mass spectrometry. 
All samples were analysed using two different chromato-
graphic techniques; i.e., reversed phase (RP) and hydro-
philic interaction chromatography (HILIC). In addition, 
data were acquired in both ionization polarities; i.e., ESI 
positive (ESI+) and ESI negative (ESI−).
Non‑targeted metabolomics data analysis
Data collection and statistical analysis
The LC–MS data was collected using the vendor’s soft-
ware MassHunter Qualitative Analysis B.05.00 (Agi-
lent Technologies), where the ions were extracted to 
compounds utilising the “Find by molecular feature” 
algorithm. The data were output as compound exchange 
format (.cef ) files into the Mass Profiler Professional 
software (MPP 2.2, Agilent Technologies) for compound 
alignment and data pre-processing. In order to reduce 
noise and remove insignificant metabolite features, only 
the features found in at least 50  % of the samples were 
included in the analysis. This resulted in a dataset com-
prising 7058 features in four separate analytical runs 
[1462 in HILIC ESI(+), 1483 in HILIC ESI(−), 2624 in RP 
ESI(+), and 1489 in RP ESI(−)].
The four datasets were exported into Microsoft Excel 
(2013), and filtered according to peak area  >20,000 to 
exclude small and insignificant features from further 
analysis. To investigate the associations between the 
peak areas of the metabolites and each of the ADHD-
like behavioural scores (total, inattention and impulsivity 
scores), the Spearman correlation analysis was used. The 
results were adjusted for multiple comparisons by the 
Benjamini-Hochberg false discovery rate (FDR) correc-
tion [18] used in each of the four analytical approaches. 
Only metabolites with praw  <0.05 were included in the 
identification analysis, and metabolites with pFDR <0.05 
were considered statistically significant. Finally, the 
remaining features in the lists were inspected in the LC–
MS chromatograms and spectra using the MassHunter 
software to locate chromatographic peaks with poor 
retention time accuracy and peak symmetry, which were 
removed from downstream analysis. Peak lists were also 
investigated to ensure that the molecular ion of a com-
pound was included into automatic MS/MS fragmenta-
tion, and if not, targeted MS/MS analysis was performed.
To investigate whether sex, age or fasting status had 
any effects on the associations between the metabolites 
and ADHD-like behavioural scores, a partial correlation 
analysis including sex, age and fasting status as covari-
ates was performed. All the statistical analyses were 
performed using the R project for Statistical Computing 
version 3.0.1.
Identification of the molecular features in the LC–MS data
The identification of metabolites was based on the accu-
rate mass and isotope information; i.e., ratios, abun-
dances and spacing, as well as product ion spectra (MS/
MS) acquired either in the automatic MS/MS analysis, 
during the initial data acquisition, or via re-injection of 
the samples in targeted MS/MS mode. The spectra were 
compared with the METLIN Metabolite Database [19], 
the Human Metabolome Database (HMDB) [20], and 
LipidMaps [21] or fragmentation patterns reported in 
earlier publications. The identification of lipids was based 
on their characteristic fragmentation patterns reported 
in earlier publications [22–25]. Briefly, the key elements 
for identification were the protonated head group (m/z 
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184.07 for PCs and LysoPCs and m/z 196.03 for LysoPEs), 
as well as the deprotonated fatty acid fragments visible in 
the negative ionization mode. For LysoPCs, the product 
ion at m/z 104 was used to distinguish sn-1 and sn-2 iso-
mers. The MS/MS fragmentation data for all of the iden-
tified metabolites is presented in Table 1.
Results
In this study, we used non-targeted LC–MS-based 
metabolite profiling to create the plasma metabolite pro-
files of 22 German Shepherds with varying ADHD-like 
behavioural scores describing the hyperactive, impulsive 
and inattentive behaviour of the dog. The variation in the 
dietary profiles was controlled by feeding the same food 
to all dogs for a 2-week period prior to sampling.
From the LC–MS measurements, we were able to 
extract 7058 molecular features to downstream statistical 
analysis. Of these, 649 features correlated with ADHD-
like behavioural scores (praw  <0.05). These molecular 
features were subjected to manual inspection to identify 
metabolites, resulting in a set of 22 identified and five 
unidentified metabolites (Table 1).
Tryptophan metabolites are associated with ADHD‑like 
behaviour
Three molecules related to tryptophan metabolism cor-
related with the ADHD-like behavioural scores (Table 2; 
Fig.  1). Compounds with m/z 190.086 and retention 
time (rt) 5.77  min and m/z 190.050 and rt 3.23  min in 
RP ESI(+) analysis showed identical fragmentation with 
3-indolepropionic acid (IPA) (CAS No. 830-96-6) and 
kynurenic acid (KYNA) (CAS No. 492-27-3), respec-
tively, according to the METLIN database (Table  1). 
Compound with m/z 176.071 and rt 5.01 in RP ESI(+) 
analysis was identified as indoleacetic acid (IAA) (CAS 
No. 87-51-4), based on its MS/MS fragmentation pat-
tern. Higher ADHD-like behavioural scores were associ-
ated with lower plasma levels of IPA (total: rs = −0.565, 
praw  =  0.006, pFDR  =  0.381; inattention: rs  =  −0.618, 
praw  =  0.002, pFDR  =  0.241; impulsivity: rs  =  −0.452, 
praw  =  0.035, pFDR  =  0.560) and IAA (inattention: 
rs  =  −0.474, praw  =  0.030, pFDR  =  0.433) (Table  2; 
Fig.  1). In contrast, high ADHD-like behavioural scores 
were associated with high plasma levels of KYNA (total: 
rs  =  0.511, praw  =  0.015, pFDR  =  0.426; inattention: 
rs  =  0.505, praw  =  0.017, pFDR  =  0.392; impulsivity: 
rs = 0.498, praw = 0.018, pFDR = 0.447).
More intense ADHD‑like behaviour is associated 
with decreased plasma phospholipids, but increased fatty 
acids
The majority of the identified metabolites in the 
plasma of dogs with ADHD-like behaviours were 
phospholipids, including five phosphatidylcholines (PC) 
(PC(18:3/18:2), PC(20:5/18:3), PC(20:4/14:0), PC(18:2/16:1) 
and PC(15:0/18:2)), five lysophosphatidylcholines 
(LysoPC) (sn-1 LysoPC(18:3), sn-1 LysoPC(14:0), sn-1 
LysoPC(15:0), sn-1 LysoPC(17:0) and sn-1 LysoPC(20:3)) 
and four lysophosphatidylethanolamines (LysoPE) (sn-1 
LysoPE(18:2), sn-1 LysoPE(20:5), sn-1 LysoPE(18:1) and 
sn-1 LysoPE(18:0)) (Table  1). All of these detected phos-
pholipids negatively correlated with the ADHD-like behav-
ioural scores, of which sn-1 LysoPC(18:3), sn-1 LysoPE(18:2) 
and PC(18:3/18:2) had the strongest associations (Table 2; 
Fig.  1). The relationships between sn-1 LysoPC(18:3) and 
all three ADHD-like behavioural scores (total: rs = −0.769, 
praw = 2.93E − 05, pFDR = 0.016; inattention: rs = −0.740, 
praw =  8.26E-05, pFDR =  0.030; impulsivity: rs = −0.765, 
praw = 3.32E-05, pFDR = 0.036), sn-1 LysoPE(18:2) and inat-
tention score (rs = −0.697, praw = 3.1E-04, pFDR = 0.044), 
and PC(18:3/18:2) and total and inattention scores (total: 
rs = −0.804, praw =  1.91E-05, pFDR =  0.016; inattention: 
rs = −0.798, praw = 2.53E-05, pFDR = 0.019) also remained 
significant after FDR correction. Significant correlations 
were not due to outliers (Additional file 3: Figure S1).
In addition, two fatty acids were identified as ara-
chidonic acid (C20:4; m/z 303.235) and C18:1 (m/z 
283.26428) (Table  1). In contrast to phospholipids, 
higher ADHD-like behavioural scores were associated 
with higher plasma levels of C20:4 (total: rs  =  0.508, 
praw  =  0.016, pFDR  =  0.163; inattention: rs  =  0.579, 
praw = 0.005, pFDR = 0.102) and C18:1 (total: rs = 0.509, 
praw  =  0.016, pFDR  =  0.426; inattention: rs  =  0.532, 
praw  =  0.011, pFDR  =  0.342; impulsivity: rs  =  0.447, 
praw = 0.025, pFDR = 0.492) (Table 2; Fig. 1).
ADHD‑like behavioural scores also correlate with other 
plasma metabolites
The metabolite with m/z 585.270 and rt 11.35 in the RP 
ESI(+) analysis correlated positively with all three ADHD-
like behavioural scores (total: rs  =  0.513, praw  =  0.015, 
pFDR  =  0.426; inattention: rs  =  0.580, praw  =  0.005, 
pFDR  =  0.271; impulsivity: rs  =  0.452, praw  =  0.035, 
pFDR =  0.560) and was identified as bilirubin (CAS No. 
635-65-4) (Tables  1, 2; Fig.  1). The metabolite with m/z 
137.071 and rt 2.22 in the HILIC(+) analysis was identified 
as 1-methylnicotinamide (CAS No. 3106-60-3). It had a 
positive association with all three ADHD-like behavioural 
scores (total: rs = 0.647, praw = 0.001, pFDR = 0.618; inat-
tention: rs = 0.668, praw = 6.86E-04, pFDR = 0.455; impul-
sivity: rs = 0.571, praw = 0.005, pFDR = 0.461).
The majority of the identified plasma metabolites correlate 
with all three ADHD‑like behavioural scores
Twenty out of the 27 reported metabolites correlated 
with all three ADHD-like behavioural scores (total, 
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Table 1 Characteristics of  the putatively identified marker metabolites in  liquid chromatography-mass spectrometry 
analysis
Column Ionization mode MW m/z RT (min) Putative annotation CID (eV) MS/MS fragmentation Identification 
referencea
HILIC ESI+ 231.148 232.155 1.59 Unknown metabolite, 
putative carnitine
10 232.1531, 85.0290, 
173.0782, 95.0856, 
60.0803
MS/MS
HILIC ESI+ 136.064 137.071 2.22 1-methylnicotinamide 20 94.0654, 137.0688, 
65.0379, 77.0375
MID274
RP ESI+ 189.043 190.050 3.23 Kynurenic acid (KYNA) 10 190.0496, 144.0443, 
172.0426
MID5683
HILIC ESI− 165.079 164.071 3.91 Phenylalanine 10 164.0713, 103.0565, 
147.0448, 90.0116, 
72.0086
MID28
RP ESI+ 175.064 176.071 5.01 Indoleacetic acid 10 130.0656, 176.0780, 
51.0227, 158.0587
HMDB 00197
RP ESI+ 189.079 190.086 5.77 3-Indolepropionic acid 
(IPA)
10 130.0655, 55.0184, 
172.0754, 190.0862
MID6602
HILIC ESI+ 220.143 221.150 7.30 Unknown metabolite 10 221.1465, 84.0806, 
87.0429, 90.9738, 
203.1374
MS/MS
RP ESI+ 467.303 468.310 9.76 sn-1 LysoPC(14:0) 40 184.0741, 86.0970, 
125.0017, 60.0814, 
104.1076; ESI(−) 10 eV: 
227.1995, 452.2768, 
512.3016
MS/MS
RP ESI− 563.323 562.316 9.85 sn-1 LysoPC(18:3) 10 502.2892, 277.2167, 
562.3029; ESI(+) 20 eV: 
184.0740, 104.1083
MS/MS
RP ESI+ 499.271 500.278 9.87 sn-1 LysoPE(20:5) 10 500.2786, 359.2548; 
ESI(−) 20 eV: 498.2860, 
169.1368, 301.2172
MS/MS
RP ESI+ 481.319 482.326 10.03 sn-1 LysoPC(15:0) 20 184.0751, 104.1059, 
482.3264; ESI(−) 10 eV: 
241.2097, 466.2915
MS/MS
RP ESI− 477.287 476.280 10.12 sn-1 LysoPE(18:2) 20 279.2321, 196.0390, 
140.0058, 78.9594, 
476.2834; ESI(+) 10 eV: 
478.2932, 337.2703
MS/MS
RP ESI− 479.302 478.295 10.29 sn-1 LysoPE(18:1) 10 281.2477, 478.2945, 
196.0306; ESI(+) 10 eV: 
480.3077, 44.0505, 
62.0614, 339.2930, 
462.3008
MS/MS
RP ESI+ 545.350 546.357 10.29 sn-1 LysoPC(20:3) 10 546.3626, 104.1084, 
184.0740; ESI(−) 10 eV: 
530.3529, 305.2466, 
590.3485
MS/MS
RP ESI+ 509.350 510.357 10.42 sn-1 LysoPC(17:0) 20 184.0740, 104.1066, 
510.3602; ESI(−) 10 eV: 
494.3250, 269.2425, 
554.3709
MS/MS
RP ESI− 481.319 480.313 10.65 sn-1 LysoPE(18:0) 10 283.2631, 480.3112, 
196.0353; ESI(+) 10 eV: 
341.3049, 482.3239, 
44.0494, 464.3121
MS/MS
RP ESI− 304.241 303.235 10.70 Arachidonic acid (C20:4) 10 303.2354, 59.0219, 
259.2326
LipidMaps
RP ESI− 643.406 642.398 10.72 Unknown metabo-
lite, putative 
GlcCer(d18:1/12:0) or 
GlcCer(d14:1/16:0)
20 642.3955, 362.1501, 
363.1579, 99.9224
Hsu and Turk [25]
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inattention and impulsivity) (Table  2; Fig.  1). Twenty-
two metabolites correlated with the total ADHD score 
and 26 with the inattention score. The metabolites sn-1 
LysoPC(14:0), sn-1 LysoPC(18:1) and unknown PC with 
m/z 796.516 correlated only with the inattention score. 
The impulsivity score correlated with 21 metabolites, and 
phenylalanine was found to specifically correlate only 
with the impulsivity score.
Age, sex and fasting have minor effects on the association 
between metabolites and ADHD‑like behavioural scores
Since there were differences in the fasting status of 
the dogs (Additional file  2: Table S2), we wanted 
to determine whether this had any effects on the 
observed correlations between the plasma metabo-
lites and ADHD-like behavioural scores. Also, the pos-
sible effects of age and sex were analysed. Correlation 
coefficients and p-values adjusted for age, sex and fast-
ing are represented in Table 3 together with the original 
p-values. Most of the associations between the metabo-
lites and ADHD-like behavioural scores remained after 
controlling for age, sex and fasting status (age, sex and 
fasting adjusted p value < 0.05). However, age, sex and 
fasting had significant effects on associations between 
IPA and the impulsivity score (original p  =  0.035, 
adjusted p  =  0.058), sn-1 LysoPC(14:0) and the inat-
tention score (original p =  0.049, adjusted p =  0.102), 
sn-1 LysoPC(17:0) and the inattention score (original 
p = 0.041, adjusted p = 0.055), unknown PC with m/z 
796.516 and the inattention score (original p  =  0.029, 
adjusted p  =  0.087), IAA and the inattention score 
(original p  =  0.03, adjusted p  =  0.062), phenylalanine 
and the impulsivity score (original p =  0.049, adjusted 
p = 0.063), and unknown metabolite with m/z 221.150 
Metabolites with uncertain identity are also included. The characteristics include the identification references together with parameters for the LC–MS analysis, 
including the chromatography (column), ionization mode in the mass spectrometry (Ionization mode), MW molecular weight, identified ion (m/z), RT retention time, 
CID collision-induced dissociation energy, MS/MS fragments fragment ions in the tandem mass spectrometry
LysoPC lysophosphatidylcholine, LysoPE lysophosphatidylethanolamine, PC phosphatidylcholine
a Identification of metabolites is based on manual MS/MS spectral interpretation, METLIN ID when MS/MS spectrum available, commercial standard compound or 
some fragmentation patterns published earlier [25]
Table 1 continued
Column Ionization mode MW m/z RT (min) Putative annotation CID (eV) MS/MS fragmentation Identification 
referencea
RP ESI+ 282.257 283.264 10.94 C18:1 10 283.2847, 43.0540, 
71.0867, 149.1310, 
57.0704, 101.0773
LipidMaps
RP ESI− 647.438 646.431 10.94 Unknown metabo-
lite, putative 
Cer(d18:1/24:1)
40 99.9224, 364.1699, 
281.2448, 365.1777, 
83.9307, 320.1746, 
646.4291
Hsu and Turk [25]
RP ESI+ 584.263 585.270 11.35 Bilirubin 10 299.1388, 585.2677 MID81
RP ESI− 847.538 846.532 11.56 PC(20:5/18:3) 40 303.2314, 102.9687, 
301.2127; ESI(+) 20 eV: 
184.0735, 802.5399
MS/MS
RP ESI− 797.523 796.516 11.59 Unknown PC 10 736.4868, 796.5069; 
ESI(+) 20 eV: 184.0733, 
752.5218
MS/MS
RP ESI− 799.538 798.531 11.81 PC(20:4/14:0) 20 738.5067, 303.2318, 
227.1970, 798.5315; 
ESI(+) 10 eV: 754.5405, 
184.0726
MS/MS
RP ESI− 825.555 824.547 11.83 PC(18:3/18:2) 20 764.5239, 824.5378, 
277.2097, 279.2388, 
45.0065; ESI(+) 20 eV: 
184.0740, 780.5574, 
86.0961
MS/MS
RP ESI− 801.553 800.547 12.04 PC(18:2/16:1) 20 740.5268, 279.2323, 
253.2152, 800.5403; 
ESI(+) 10 eV: 756.5574, 
184.0733
MS/MS
RP ESI+ 743.549 744.556 12.08 PC(15:0/18:2) 10 744.5577, 184.0743; 
ESI(−) 20 eV: 728.5133, 
788.5291, 241.2161, 
279.2331
MS/MS
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and the total ADHD score (original p = 0.039, adjusted 
p = 0.069).
Discussion
ADHD is a prevalent and severe neuropsychiatric disor-
der, but yet poorly characterised for underlying genes and 
molecular networks. Genetic complexity and clinical het-
erogeneity have challenged the research, warranting new 
approaches to identify novel biomarkers and pathways. 
An alternative approach would be a study of a physiologi-
cally relevant large animal model with natural ADHD-
like behaviours such as the dog [15]. Here, we applied 
a methodologically well-controlled pilot non-targeted 
metabolite profiling of canine ADHD-like behaviours in 
order to investigate the correlation between the plasma 
metabolite profiles and ADHD-like behavioural scores of 
German Shepherds with varying ADHD-like behaviours. 
We report 27 metabolites that correlated with at least one 
of the three ADHD-like behavioural scores (total, inat-
tention, impulsivity). The identified ADHD-like behav-
iour-related candidate metabolites indicate alterations 
in tryptophan and phospholipids metabolisms. The same 
pathways have been suggested in human ADHD [26–30], 
and the possible important overlap in the human and 
canine pathways warrants a larger replication study in 
dogs prior to further conclusions of the metabolic simi-
larity of the ADHD models.
We found three interesting metabolites in the trypto-
phan pathway, IPA, IAA and KYNA. Lower plasma IPA 
and IAA levels were associated with higher ADHD-
like behavioural scores. IPA is a microbial deamination 
product of dietary tryptophan with antioxidant capacity 
[31, 32], produced solely by enteric bacteria (including 
Clostridium sporogenes) in the intestines [33–35] (Fig. 2). 
Table 2 Associations between  the plasma metabolites and  ADHD-like behavioural scores (total ADHD, inattention, 
impulsivity)
Spearman correlation coefficients (rs) with statistical significance (praw and pFDR)
Putative annotation Total ADHD Inattention Impulsivity
rs praw pFDR rs praw pFDR rs praw pFDR
Putative carnitine 0.505 0.017 0.990 0.450 0.036 0.990 0.509 0.016 0.797
1-methylnicotinamide 0.647 0.001 0.618 0.668 6.86E-04 0.455 0.571 0.005 0.461
Kynurenic acid (KYNA) 0.511 0.015 0.426 0.505 0.017 0.392 0.498 0.018 0.447
Phelynalanine 0.403 ns ns 0.337 ns ns 0.425 0.049 0.989
Indoleacetic acid −0.404 ns ns −0.474 0.030 0.433 −0.349 ns ns
3-Indolepropionic acid (IPA) −0.565 0.006 0.381 −0.618 0.002 0.241 −0.452 0.035 0.560
Unknown metabolite m/z 221.150 0.443 0.039 0.990 0.520 0.013 0.873 0.287 ns ns
sn-1 LysoPC(14:0) −0.390 ns ns −0.424 0.049 0.510 −0.360 ns ns
sn-1 LysoPC(18:3) −0.769 2.93E-05 0.016 −0.740 8.26E-05 0.030 −0.765 3.32E-05 0.036
sn-1 LysoPE(20:5) −0.544 0.009 0.409 −0.615 0.002 0.241 −0.447 0.037 0.560
sn-1 LysoPC(15:0) −0.623 0.002 0.330 −0.602 0.003 0.241 −0.659 8.46E-04 0.320
sn-1 LysoPE(18:2) −0.630 0.002 0.093 −0.697 3.1E-04 0.044 −0.549 0.008 0.230
sn-1 LysoPE(18:1) −0.382 ns ns −0.530 0.011 0.117 −0.218 ns ns
sn-1 LysoPC(20:3) −0.508 0.016 0.426 −0.489 0.021 0.409 −0.516 0.014 0.437
sn-1 LysoPC(17:0) −0.451 0.035 0.491 −0.438 0.041 0.473 −0.441 0.038 0.566
sn-1 LysoPE(18:0) −0.562 0.006 0.146 −0.574 0.005 0.102 −0.539 0.01 0.232
Arachidonic acid (C20:4) 0.508 0.016 0.163 0.579 0.005 0.102 0.355 ns ns
Unknown metabolite, putative GlcCer(d18:1/12:0)  
or GlcCer(d14:1/16:0)
0.504 0.017 0.163 0.524 0.012 0.117 0.447 0.037 0.302
C18:1 0.509 0.016 0.426 0.532 0.011 0.342 0.477 0.025 0.492
Unknown metabolite, putative Cer(d18:1/24:1) 0.509 0.016 0.163 0.536 0.010 0.117 0.461 0.031 0.283
Bilirubin 0.513 0.015 0.426 0.580 0.005 0.271 0.452 0.035 0.560
PC(20:5/18:3) −0.555 0.009 0.150 −0.621 0.003 0.087 −0.415 ns ns
Unknown PC m/z 796.516 −0.413 ns ns −0.465 0.029 0.173 −0.299 ns ns
PC(20:4/14:0) −0.558 0.007 0.148 −0.557 0.007 0.110 −0.485 0.022 0.281
PC(18:3/18:2) −0.804 1.91E-05 0.016 −0.798 2.53E-05 0.019 −0.731 2.52E-04 0.137
PC(18:2/16:1) −0.518 0.013 0.163 −0.500 0.018 0.137 −0.486 0.022 0.281
PC(15:0/18:2) −0.578 0.005 0.381 −0.568 0.006 0.305 −0.525 0.012 0.416
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IAA is a plant hormone of the auxin class synthesised via 
multiple pathways in the plants [36], but it can also be 
produced in mammals from tryptophan in tissues, and in 
the intestines by enteric bacteria (including Clostridium 
bartlettii) [37, 38]. Due to the intestinal bacterial produc-
tion of both IPA and IAA by bacteria belonging to the 
same genus (Clostridium), negative correlations between 
the ADHD-like behavioural scores and these metabolites 
suggest differences in intestinal microbiota of dogs with 
different ADHD-like behaviours, since there were no dif-
ferences in the diets (and intake of tryptophan) of the 
dogs. Gut microbiota may have a bidirectional effect on 
the nervous and the immune systems [39–41]. Since IPA 
is capable of crossing the blood–brain barrier (BBB) and 
is known to have neuroprotective actions in the central 
nervous system (CNS) [35], decreased IPA may predis-
pose dogs to neurological and behavioural abnormalities 
due to oxidative stress, for example. Alternatively, stress 
caused by hyperactive and impulsive behaviour may lead 
to altered gut microbiota and result in changed plasma 
IPA. Changes in the gut microbiota have been suggested 
in neuro behavioural disorders such as mood disorders 
and autism [40].
The third metabolite in the tryptophan pathway, 
KYNA, was positively correlated with the ADHD-like 
behavioural scores. KYNA is a neuroactive metabo-
lite produced in the kynurenine pathway of trypto-
phan metabolism [42, 43]. It acts as an endogenous 
antagonist of the cholinergic nicotinic α7-receptor 
(α7nAChR) and the glutamatergic N-methyl-d-aspar-
tate receptor (NMDAR) in the CNS and as an agonist 
of a particular G-protein coupled receptor, GPR35, 
in immune cells and in the gastrointestinal (GI) tract 
[44]. Interestingly, altered levels of KYNA have been 
proposed in schizophrenia [45, 46], depression [47] 
and bipolar disorder [48]. A recent study demonstrated 
a reduction in serum KYNA levels in adult ADHD 
patients, when compared with controls [26]. Interest-
ingly, our data showed a positive relationship between 
the plasma KYNA levels and ADHD-like behavioural 
scores in adult dogs, indicating that dogs with more 
intense ADHD-like behaviour had higher KYNA levels. 
KYNA is mainly produced via tryptophan catabolism 
in various tissues, but enteric bacteria in the intestines 
are also capable of converting dietary tryptophan into 
KYNA [49, 50] (Fig.  2). Higher plasma KYNA levels 
may be due to increased bacterial production of KYNA 
in the intestines or increased catabolism of tryptophan 
via the kynurenine pathway in the tissues resulting, 
for example, from inflammation or oxidative stress 
[51]. Thus, there may be less tryptophan available for 
transport into the brain for serotonin synthesis. Sero-
tonin, in turn, is an important neurotransmitter, regu-
lating impulsivity and social behaviour [52]. Decreased 
serotonin levels have been reported in ADHD patients 
[52]. Thus, the positive correlation between the plasma 
KYNA levels and ADHD-like behavioural scores may 
indirectly reflect decreased serotonin levels with 
Fig. 1 Correlation plot between metabolites and ADHD-like behavioural scores. Red and blue circles indicate positive and negative correlations, 
respectively. *praw < 0.05, **praw < 0.01, ***praw < 0.001, 
#pFDR < 0.05
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characteristic behavioural symptoms in dogs with 
higher ADHD-like behavioural scores.
We observed strong and negative correlations between 
ADHD-like behavioural scores and fifteen phospholipids, 
including five PCs, five LysoPCs, four LysoPEs and one 
unknown PC. The blood lipid composition is affected by 
nutrition and fasting [53], and we, therefore, changed the 
diet of all study dogs and controlled fasting in the sta-
tistical analysis. Thus, the observed difference suggests 
alterations in the endogenous phospholipid metabolism 
or in the absorption of dietary lipids between the study 
groups. Phospholipids are important signalling mole-
cules and major components of cell membranes regulat-
ing membrane fluidity, charge and receptor function [54, 
55]. The adequate amount of brain phospholipids and 
their right fatty acid composition is especially important 
to ensure optimal membrane functionality in the brain 
[55]. Regarding this, the lower plasma phospholipids may 
have negative effects on the physiology and behaviour of 
dogs with more intense ADHD-like behaviour.
Phospholipids are composed of hydrophobic and 
hydrophilic parts, which are joined together by glycerol 
[56]. The hydrophilic part consists of a phosphate group 
combined with a characteristic head group (choline in 
PCs and ethanolamine in PEs), whereas the hydrophobic 
part consists of different kinds of combinations of fatty 
acids, PCs containing two fatty acids, whereas LysoPCs 
and LysoPEs contain only one fatty acid [56]. Thus, the 
composition of phospholipids depends on the availabil-
ity of free fatty acids, which are incorporated into phos-
pholipids. Interestingly, both human [27, 28, 30, 57] and 
rodent [58–61] studies have suggested that the omega-3 
Table 3 Age, sex and fasting-adjusted associations between the plasma metabolites and ADHD-like behavioural scores
Spearman correlation coefficients (corrected rs) from partial correlation analysis including age, sex and fasting status as covariates together with statistical significance 
(adjusted p). Original p values are also shown (original p)
Putative annotation Total ADHD Inattention Impulsivity
Original Adjusted Original Adjusted Original Adjusted
p rs p p rs p p rs p
Putative carnitine 0.017 0.560 0.013 0.036 0.527 0.02 0.016 0.526 0.021
1-methylnicotinamide 0.001 0.642 0.003 6.86E-04 0.671 0.002 0.005 0.576 0.010
Kynurenic acid (KYNA) 0.015 0.519 0.023 0.017 0.486 0.035 0.018 0.543 0.016
Phelynalanine ns ns ns ns ns ns 0.049 0.435 0.063
Indoleacetic acid ns ns ns 0.030 −0.448 0.062 ns ns ns
3-Indolepropionic acid (IPA) 0.006 −0.578 0.010 0.002 −0.655 0.002 0.035 −0.442 0.058
Unknown metabolite m/z 221.150 0.039 0.426 0.069 0.013 0.475 0.040 ns ns ns
sn-1 LysoPC(14:0) ns ns ns 0.049 −0.387 0.102 ns ns ns
sn-1 LysoPC(18:3) 2.93E-05 −0.782 7.54E-05 8.26E-05 −0.765 1.34E-04 3.32E-05 −0.785 6.86E-05
sn-1 LysoPE(20:5) 0.009 −0.569 0.011 0.002 −0.615 0.005 0.037 −0.499 0.030
sn-1 LysoPC(15:0) 0.002 −0.640 0.003 0.003 −0.598 0.007 8.46E-04 −0.701 8.0E-04
sn-1 LysoPE(18:2) 0.002 −0.670 0.002 0.003 −0.703 8.0E-04 0.008 −0.645 0.003
sn-1 LysoPE(18:1) ns ns ns 0.011 −0.493 0.032 ns ns ns
sn-1 LysoPC(20:3) 0.016 −0.550 0.015 0.021 −0.555 0.014 0.014 −0.561 0.013
sn-1 LysoPC(17:0) 0.035 −0.463 0.046 0.041 −0.447 0.055 0.038 −0.499 0.030
sn-1 LysoPE(18:0) 0.006 −0.610 0.006 0.005 −0.622 0.004 0.01 −0.600 0.007
Arachidonic acid (C20:4) 0.016 0.502 0.029 0.005 0.555 0.014 ns ns ns
Unknown metabolite, putative GlcCer(d18:1/12:0) 
or GlcCer(d14:1/16:0)
0.017 0.514 0.024 0.012 0.547 0.015 0.037 0.473 0.041
C18:1 0.016 0.508 0.026 0.011 0.524 0.021 0.025 0.505 0.028
Unknown metabolite, putative Cer(d18:1/24:1) 0.016 0.506 0.027 0.010 0.529 0.020 0.031 0.488 0.034
Bilirubin 0.015 0.511 0.025 0.005 0.544 0.016 0.035 0.515 0.024
PC(20:5/18:3) 0.009 −0.601 0.008 0.003 −0.615 0.007 ns ns ns
Unknown PC m/z 796.516 ns ns ns 0.029 −0.404 0.087 ns ns ns
PC(20:4/14:0) 0.007 −0.559 0.013 0.007 −0.538 0.017 0.022 −0.531 0.019
PC(18:3/18:2) 1.19E-05 −0.804 9.91E-05 2.53E-05 −0.785 1.89E-04 2.52E-04 −0.767 3.24E-04
PC(18:2/16:1) 0.013 −0.529 0.020 0.018 −0.537 0.018 0.022 −0.476 0.039
PC(15:0/18:2) 0.005 −0.604 0.006 0.006 −0.578 0.010 0.012 −0.590 0.008
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Fig. 2 Simplified illustration of the possible metabolic pathways of dietary tryptophan in the intestines. Dietary tryptophan can be degraded in the 
intestines by enteric bacteria to produce IAA and IPA or KYNA via kynurenine. From the intestines, IPA, IAA and KYNA are transferred to circulation. 
IPA is known to cross BBB, and thus, can migrate to CNS and act there, but the ability of IAA and KYNA to cross BBB is uncertain. In addition to the 
degradation of dietary tryptophan in the intestines, KYNA and IAA can also be synthetised from tryptophan in various other tissues in the body, but 
IPA is solely produced in the intestines by enteric bacteria. BBB blood–brain barrier, CNS central nervous system, IAA indoleacetic acid, IDO indoleam-
ine 2,3-dioxygenase, IPA 3-indolepropionic acid, KYNA kynurenic acid
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polyunsaturated fatty acid (PUFA) status may contribute 
to the etiology of ADHD. Both children and adult ADHD 
patients have been demonstrated to have decreased pro-
portions of long chain PUFAs (LC-PUFAs) and espe-
cially omega-3 PUFAs, like eicosapentaenoic acid (EPA; 
20:5 n-3) and docosahexaenoic acid (DHA; 22:6 n-3), in 
plasma lipids when compared with control subjects [28, 
29, 62–65].
It has been suggested that the relationship between 
decreased omega-3 PUFAs and ADHD would lie in 
dopamine neurotransmission, as rodent studies have 
proposed that chronic omega-3 PUFA deficiency is asso-
ciated with significantly decreased concentrations of 
endogenous dopamine and reduced dopamine-2 (D2) 
receptor binding in the frontal cortex [59, 61], accom-
panied by attentional and behavioural problems when 
compared to rodents fed with diet containing adequate 
levels of PUFAs [66]. In this study, ADHD-like behav-
ioural scores negatively correlated with plasma phos-
pholipids containing combinations of omega-3 (18:3 
n-3 (ALA), 20:5 n-3 (EPA)) and omega-6 (18:2 n-6 (LA)) 
fatty acids. Our results are not directly comparable to 
those findings made in ADHD patients, but indicate 
that phospholipid abnormalities could contribute to 
canine ADHD-like behaviours too. In contrast to phos-
pholipids, ADHD-behavioural scores were positively 
associated with plasma levels of free fatty acids C20:4 
and C18:1. This may refer to an increased breakdown of 
phospholipids or problems in the phospholipid synthe-
sis, rather than problems in the intestinal absorption of 
dietary fatty acids.
Our study also suggests the involvement of oxidative 
stress in canine ADHD-like behaviours. The ADHD-like 
behavioural scores showed a positive relationship with 
fatty acid C20:4, an oxidative stress marker, but a nega-
tive relationship with the antioxidant IPA. Impaired bal-
ance between the oxidant and antioxidant systems and 
increased levels of oxidative stress have already been 
demonstrated in ADHD, although precise mechanisms 
remain to be characterised [67–70].
We have previously demonstrated the promise of the 
metabolomics approach in canine fear research [17], 
and now, we have applied this approach to study canine 
ADHD-like behaviours with better optimised method-
ology and preparation of the study cohort. Instead of 
whole blood, we used fresh plasma samples from dogs 
that had undergone a controlled diet change before 
the sampling. However, we have several limitations in 
our study. First, our sample size is small for conclusive 
results. Second, we must acknowledge that the behav-
ioural survey is based on the owner reports of the behav-
iours and activity levels of the dogs, and no behavioural 
testing was performed to verify the owner reports. 
Thirdly, fasting control was incomplete, as some dogs 
failed it. Finally, the time of sampling varied from day-
time to evening and should be less variable in the future 
to better control possible variations due to the circadian 
rhythm.
Conclusions
Our metabolomics study suggests associations between 
canine ADHD-like behaviours and tryptophan and phos-
pholipid metabolisms. A replication study with a larger 
sample size is needed to validate our findings and to con-
firm the overlap in the affected pathways between human 
ADHD and canine ADHD-like behaviours.
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